Answers are grounded in this paper and cite their sources.
This review explores how tumor stroma contributes to therapy resistance, highlighting potential therapeutic strategies.
INTRODUCTION: The tumor microenvironment (TME), consisting of cellular components, such as cancer, immune, and stromal cells, and the extracellular matrix, plays a central role in tumor initiation, progression, metastasis, and therapeutic resistance. While immune-targeted therapies, including immune checkpoint inhibitors and CAR-T cells, have achieved major breakthroughs, stromal cells are increasingly recognized as key regulators of tumor biology. AREAS COVERED: Stromal cells influence tumor metabolism, immune evasion, angiogenesis, and drug resistance. They may arise from surrounding nonmalignant tissues or through cellular transdifferentiation, exerting both tumor-promoting and tumor-suppressive functions depending on context. Current strategies exploit stromal elements such as hyaluronic acid and laminin for targeted drug delivery or remodel the stroma to improve treatment response. Novel drug delivery systems designed to engage stromal components demonstrate enhanced penetration, specificity, safety, and biocompatibility, with promising clinical trial results. Furthermore, understanding the roles of cancer-associated fibroblasts, mesenchymal stem cells, tumor-associated adipocytes, endothelial cells, and pericytes offers new therapeutic opportunities. Articles of relevance were sourced from PubMed, Scopus, and Web of Science, covering works published until April 2025. EXPERT OPINION: Targeting the tumor stroma represents a promising frontier in oncology. Beyond enabling advanced drug delivery systems, it provides deeper insights into tumor biology and mechanisms of treatment resistance, paving the way for more effective, context-specific therapies.
No takes yet. Share an insight, caveat, or question.
Luong et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: